IART Integra Lifesciences Holdings Corp

Price (delayed)

$68.34

Market cap

$5.77B

P/E Ratio

43.25

Dividend/share

N/A

EPS

$1.58

Enterprise value

$6.95B

Sector: Healthcare
Industry: Medical Devices

Highlights

IART's EPS has surged by 168% year-on-year and by 136% since the previous quarter
Integra Lifesciences Holdings's net income has soared by 167% YoY and by 137% from the previous quarter
IART's quick ratio is down by 28% from the previous quarter but it is up by 21% YoY
The debt is up by 14% year-on-year
The gross profit has declined by 11% year-on-year

Key stats

What are the main financial stats of IART
Market
Shares outstanding
84.37M
Market cap
$5.77B
Enterprise value
$6.95B
Valuations
Price to earnings (P/E)
43.25
Price to book (P/B)
3.8
Price to sales (P/S)
4.22
EV/EBIT
42.1
EV/EBITDA
24.47
EV/Sales
5.07
Earnings
Revenue
$1.37B
EBIT
$165.1M
EBITDA
$284.09M
Free cash flow
$168.6M
Per share
EPS
$1.58
Free cash flow per share
$1.99
Book value per share
$17.98
Revenue per share
$16.21
TBVPS
$20
Balance sheet
Total assets
$3.62B
Total liabilities
$2.1B
Debt
$1.66B
Equity
$1.51B
Working capital
$836.19M
Liquidity
Debt to equity
1.09
Current ratio
3.09
Quick ratio
1.73
Net debt/EBITDA
4.17
Margins
EBITDA margin
20.7%
Gross margin
62%
Net margin
9.8%
Operating margin
11%
Efficiency
Return on assets
3.9%
Return on equity
9.6%
Return on invested capital
6.5%
Return on capital employed
5.1%
Return on sales
12%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IART stock price

How has the Integra Lifesciences Holdings stock price performed over time
Intraday
-1.3%
1 week
0.18%
1 month
-2.18%
1 year
25.76%
YTD
5.27%
QTD
5.27%

Financial performance

How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.37B
Gross profit
$851.03M
Operating income
$151.37M
Net income
$133.89M
Gross margin
62%
Net margin
9.8%
The net margin has soared by 197% year-on-year and by 139% since the previous quarter
Integra Lifesciences Holdings's net income has soared by 167% YoY and by 137% from the previous quarter
IART's operating margin has soared by 77% year-on-year and by 12% since the previous quarter
The operating income has surged by 61% year-on-year and by 12% since the previous quarter

Growth

What is Integra Lifesciences Holdings's growth rate over time

Valuation

What is Integra Lifesciences Holdings stock price valuation
P/E
43.25
P/B
3.8
P/S
4.22
EV/EBIT
42.1
EV/EBITDA
24.47
EV/Sales
5.07
IART's EPS has surged by 168% year-on-year and by 136% since the previous quarter
The stock's price to earnings (P/E) is 68% less than its 5-year quarterly average of 134.9
The P/B is 23% higher than the last 4 quarters average of 3.1 and 6% higher than the 5-year quarterly average of 3.6
The equity has increased by 8% since the previous quarter and by 7% year-on-year
The price to sales (P/S) is 36% more than the last 4 quarters average of 3.1 and 28% more than the 5-year quarterly average of 3.3
The revenue has declined by 10% year-on-year

Efficiency

How efficient is Integra Lifesciences Holdings business performance
Integra Lifesciences Holdings's return on equity has surged by 167% YoY and by 134% QoQ
IART's ROA has soared by 160% YoY and by 129% QoQ
IART's return on sales has surged by 60% year-on-year and by 11% since the previous quarter
IART's return on invested capital is up by 30% year-on-year and by 8% since the previous quarter

Dividends

What is IART's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IART.

Financial health

How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 72% higher than its total liabilities
The current ratio has declined by 32% since the previous quarter but it has grown by 19% year-on-year
IART's quick ratio is down by 28% from the previous quarter but it is up by 21% YoY
The debt is 9% greater than the equity
The equity has increased by 8% since the previous quarter and by 7% year-on-year
Integra Lifesciences Holdings's debt to equity has decreased by 7% QoQ but it has increased by 6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.